Literature DB >> 17198973

Blood-brain barrier delivery.

William M Pardridge1.   

Abstract

Neuropharmaceutics is the largest potential growth sector of the pharmaceutical industry. However, this growth is blocked by the problem of the blood-brain barrier (BBB). Essentially 100% of large-molecule drugs and >98% of small-molecule drugs do not cross the BBB. The BBB can be traversed because there are multiple endogenous transporters within this barrier. Therefore, brain drug development programs of the future need to be re-configured so that drugs are formulated to enable transport into the brain via endogenous BBB transporters.

Mesh：

Substances：

Year:  2006        PMID： 17198973     DOI： 10.1016/j.drudis.2006.10.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  316 in total

Review 1.  In vivo methods to study uptake of nanoparticles into the brain.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Wim E Hennink; Gert Storm; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-10-07       Impact factor: 4.200

Review 2.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

3.  Secreted luciferase for in vivo evaluation of systemic protein delivery in mice.

Authors:  Salim S El-Amouri; Phuong Cao; Carol Miao; Dao Pan
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

4.  Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Authors:  Sagar Agarwal; Yasuo Uchida; Rajendar K Mittapalli; Ramola Sane; Tetsuya Terasaki; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-03-08       Impact factor: 3.922

Review 5.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

6.  Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin.

Authors:  Rokon Uz Zaman; Nihal S Mulla; Keegan Braz Gomes; Cherilyn D'Souza; Kevin Sean Murnane; Martin J D'Souza
Journal:  Int J Pharm       Date:  2018-07-19       Impact factor: 5.875

7.  Calixarene-mediated liquid membrane transport of choline conjugates 3: The effect of handle variation on neurotransmitter transport.

Authors:  James L Collins; Ayu Fujii; Sahar Roshandel; Cuong-Alexander To; Michael P Schramm
Journal:  Bioorg Med Chem Lett       Date:  2017-05-05       Impact factor: 2.823

8.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

9.  Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier.

Authors:  Daren Wang; Salim S El-Amouri; Mei Dai; Chia-Yi Kuan; David Y Hui; Roscoe O Brady; Dao Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 10.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences.

Authors:  Ferenc A Jolesz; Nathan J McDannold
Journal:  Neurol Clin       Date:  2013-11-08       Impact factor: 3.806
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.